Key takeaways
Three things to remember
- 01
Lp(a) is roughly 90% genetically determined and does not meaningfully respond to diet, exercise, or standard lipid-lowering lifestyle changes.
- 02
Elevated Lp(a) above 125 nmol/L is an independent major cardiovascular risk factor that standard lipid panels miss entirely; it should be tested at least once in every adult.
- 03
If Lp(a) is elevated, the primary management strategy is aggressive LDL-C reduction to lower total atherogenic burden while awaiting specific Lp(a)-targeting therapies.
How it works
The Mechanism
Lp(a) is structurally similar to LDL but has an additional protein called apolipoprotein(a) attached via a disulfide bond. This extra protein makes Lp(a) stickier: it is more prone to depositing in arterial walls and more resistant to clearance than standard LDL particles. It also interferes with the body's ability to dissolve blood clots, adding a thrombotic risk layer on top of the atherogenic one.
Lp(a) levels are roughly 90% genetically determined. Unlike LDL-C, which responds substantially to diet and exercise, Lp(a) is nearly immune to lifestyle intervention. It is set primarily at birth by the LPA gene, varies by a factor of 1,000 across individuals, and changes less than 10-15% in response to any non-pharmacological intervention studied to date.
Because standard lipid panels do not include Lp(a), most people with elevated levels have no idea they carry the risk. European cardiovascular guidelines recommend testing Lp(a) at least once in every adult's lifetime. The American Heart Association now considers elevated Lp(a) above 125 nmol/L (roughly 50 mg/dL) a major independent cardiovascular risk factor.
In practice
Why It Matters
Test it once. It changes how you interpret everything else.
If you have elevated Lp(a), your cardiovascular risk is meaningfully higher than your LDL-C, ApoB, or triglyceride numbers alone would suggest. Knowing your Lp(a) changes the risk calculus: it is a strong argument for more aggressive LDL-C targets, earlier statin consideration, and closer monitoring. It also means that if heart disease runs in your family despite clean-looking standard lipid panels, Lp(a) may be the hidden driver.
Common misconception
Most people assume that if their LDL-C is good and they eat well, their cardiovascular risk is under control. Elevated Lp(a) operates independently of diet and exercise: you can have an LDL-C of 80 mg/dL, no metabolic dysfunction, and still carry substantially elevated cardiovascular risk if Lp(a) is above 125 nmol/L. It is not a failure of lifestyle. It is genetics, and it needs to be known.
Reference ranges
What a Healthy Range Looks Like
Normal
<75 nmol/L
No additional Lp(a)-related cardiovascular risk beyond standard LDL and metabolic factors
Borderline
75–125 nmol/L
Modest Lp(a) contribution to risk; warrants closer monitoring of other cardiovascular markers
Elevated
125–200 nmol/L
Independent major cardiovascular risk factor; impacts LDL-C targets and intervention thresholds
High Risk
>200 nmol/L
Substantially elevated risk; equivalent to familial hypercholesterolemia in cardiovascular impact
Lp(a) is sometimes reported in mg/dL and sometimes in nmol/L, and the conversion is not 1:1; 50 mg/dL is approximately 125 nmol/L but varies by assay. Confirm which unit your lab uses. Unlike most biomarkers, trending over time is less meaningful here because Lp(a) changes minimally with intervention.
Signs it is disrupted
- Family history of early cardiovascular disease (heart attack or stroke before age 55 in men, 65 in women) with otherwise clean-looking standard lipid panels
- Personal history of premature cardiovascular events despite normal LDL-C and metabolic markers
- Diagnosed familial hypercholesterolemia, which has a high prevalence of concurrent elevated Lp(a)
- Standard lipid panels look acceptable but ApoB is disproportionately elevated relative to LDL-C
What moves it
How to Improve It
Know your number. Lp(a) should be tested at least once in adulthood; it is a 1-time test rather than a regularly monitored marker because levels are genetically fixed and change minimally over a lifetime.
Lower LDL-C aggressively. If Lp(a) is elevated, the most evidence-supported strategy is driving LDL-C well below standard targets (below 70 mg/dL, or below 55 mg/dL for high-risk individuals) to reduce total atherogenic burden.
Request ApoB. ApoB captures Lp(a) particles alongside LDL particles and provides a more complete picture of atherogenic load; a single ApoB test costs roughly the same as a standard lipid panel add-on.
Monitor emerging therapies. RNA-targeting drugs (inclisiran, pelacarsen) that directly reduce Lp(a) are in late-stage trials as of 2025-2026 and may become available for high-risk individuals within the next 1-3 years.
Go deeper